This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Sign in
Sign in
Sign out

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Explore Content

Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.

Zinforo®: High clinical cure rate and evidence of rapid response in CAP

Clinical cure rates: ASIA CAP2​​​​​​​

Study design

A Phase III, prospective, multicentre (China, Taiwan, Korea, Vietnam and India), randomised, double-blind, non-inferiority with nested superiority trial comparing Zinforo (600 mg IV every 12 hours) vs ceftriaxone (2 g IV every 24 hours)

Patient population

Adult Asian patients ≥18 years of age with PORT risk class III-IV CAP. 763 patients were treated for 5-7 days and evaluated in the MITT population

Study objective

To determine non-inferiority (with nested superiority) in the clinical cure rate of Zinforo compared with ceftriaxone (2 g) in the CE population at TOC (8-15 days after end of treatment)

Secondary objectives

Clinical response at the TOC in the MITT, mMITT, and ME populations; clinical response at EOT; clinical relapse at the LFU visit in patients who were clinically cured at TOC; microbiological response at the TOC; clinical and microbiological response by pathogen at the TOC; and safety (as assessed by adverse events in the safety population)
Clinical cure was defined as total resolution of all signs and symptoms of CAP or improvement to such an extent that further antimicrobial treatment was unnecessary

Zinforo 600 mg every 12 hours demonstrated superior efficacy vs ceftriaxone 2 g every 24 hours in terms of clinical cure rates2

Non-inferiority was defined as a lower limit of the 95% CI ≥–10% for the between group difference. If this was achieved the protocol stated superiority would be concluded if the lower limit of the 95% CI ≥0%.2

The safety profile of Zinforo was similar to that observed in the pooled Phase III CAP and cSSTI studies.2-4

Explore More

Read several CAP patient profiles describing potential scenarios where Zinforo could be a treatment of choice.

Access CAP patient profiles 

To learn more about the efficacy of Zinforo in a real-world setting, explore the CAPTURE study.

View CAPTURE study data

**Zinforo is not active against Pseudomonas aeruginosa. Like other cephalosporins, Zinforo is not active against ESBL-producing strains. In vitro activity does not always correlate with clinical efficacy.1​​​​​​​

Abbreviations

​​​​​​​CAP, community-acquired pneumonia; cSSTI, complicated skin and soft tissue infections; CE, clinically evaluable; CI, confidence interval; MITT, modified intent-to-treat; PORT, Pneumonia Patient Outcomes Research Team; MRSA, Methicillin-resistant Staphylococcus aureus.

Prescribing Information​​​​​​​

Zinforo® (ceftaroline fosamil)
Great Britain
Zinforo 600 mg powder for concentrate for solution for infusion
Northern Ireland
Zinforo 600 mg powder for concentrate for solution for infusion 

References
  1. ZINFORO. Summary of Product Characteristics
  2. Zhong N, et al. Lancet Infect Dis 2015;15:161-71
  3. File TM, et al. Clin Infect Dis 2010;51:1395–405
  4. Corey G, et al. Clin Infect Dis 2010;51:641-50
  5. Laudano JB. J Antimicrob Chemother 2011;66(Suppl.3):iii11-iii18
  6. Garrison MW, et al. Expert Rev Anti Infect Ther 2012;10:1087-103
  7. Drusano, GL. J Antimicrob Chemother 2011;66(Suppl3):iii61–7
PP-ZFO-GBR-0226. September 2021

Explore the outcomes of the other Zinforo Phase III clinical trials in patients with CAP and cSSTI

Tolerability profile of Zinforo

Access data on the tolerability profile of Zinforo as established in key Phase III clinical trials.

View tolerability profile

** This is an optional area where footnotes can live.

Zinforo has an extended in vitro
spectrum of coverage, including key pathogens in CAP and cSSTI**1,5-7

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

Yes

No

OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.This is an interstitial message to prompt a HCP before they login.

If you have already registered with pfizerpro.co.uk and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.

Would you like to register or sign in now?